These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 32035709)

  • 41. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults.
    Pépin S; Donazzolo Y; Jambrecina A; Salamand C; Saville M
    Vaccine; 2013 Nov; 31(47):5572-8. PubMed ID: 24016810
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: A systematic review and meta-analysis.
    Domnich A; Arata L; Amicizia D; Puig-Barberà J; Gasparini R; Panatto D
    Vaccine; 2017 Jan; 35(4):513-520. PubMed ID: 28024956
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant.
    Vesikari T; Pellegrini M; Karvonen A; Groth N; Borkowski A; O'Hagan DT; Podda A
    Pediatr Infect Dis J; 2009 Jul; 28(7):563-71. PubMed ID: 19561422
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Influenza viruses and cross-reactivity in healthy adults: humoral and cellular immunity induced by seasonal 2007/2008 influenza vaccination against vaccine antigens and 2009 A(H1N1) pandemic influenza virus.
    Iorio AM; Bistoni O; Galdiero M; Lepri E; Camilloni B; Russano AM; Neri M; Basileo M; Spinozzi F
    Vaccine; 2012 Feb; 30(9):1617-23. PubMed ID: 22245606
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunogenicity and Safety of an MF59-adjuvanted Quadrivalent Seasonal Influenza Vaccine in Young Children at High Risk of Influenza-associated Complications: A Phase III, Randomized, Observer-blind, Multicenter Clinical Trial.
    Esposito S; Fling J; Chokephaibulkit K; de Bruijn M; Oberye J; Zhang B; Vossen J; Heijnen E; Smolenov I
    Pediatr Infect Dis J; 2020 Aug; 39(8):e185-e191. PubMed ID: 32404782
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to < 9 years of age.
    Nassim C; Christensen S; Henry D; Holmes S; Hohenboken M; Kanesa-Thasan N
    Pediatr Infect Dis J; 2012 Apr; 31(4):e59-65. PubMed ID: 22418661
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Response to 2009 pandemic influenza A (H1N1) vaccine in HIV-infected patients and the influence of prior seasonal influenza vaccination.
    Soonawala D; Rimmelzwaan GF; Gelinck LB; Visser LG; Kroon FP
    PLoS One; 2011 Jan; 6(1):e16496. PubMed ID: 21304982
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Priming with MF59 adjuvanted versus nonadjuvanted seasonal influenza vaccines in children - A systematic review and a meta-analysis.
    Patel MM; Davis W; Beacham L; Spencer S; Campbell AP; Lafond K; Rolfes M; Levine MZ; Azziz-Baumgartner E; Thompson MG; Fry AM
    Vaccine; 2020 Jan; 38(3):608-619. PubMed ID: 31735505
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunogenicity and safety of cell-derived MF59®-adjuvanted A/H1N1 influenza vaccine for children.
    Knuf M; Leroux-Roels G; Rümke H; Rivera L; Pedotti P; Arora AK; Lattanzi M; Kieninger D; Cioppa GD
    Hum Vaccin Immunother; 2015; 11(2):358-76. PubMed ID: 25621884
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunogenicity and safety of an egg-based inactivated quadrivalent influenza vaccine (GC3110A) versus two inactivated trivalent influenza vaccines with alternate B strains: A phase Ⅲ randomized clinical trial in adults.
    Song JY; Lee J; Woo HJ; Wie SH; Lee JS; Kim SW; Kim TH; Jung SI; Noh JY; Choi WS; Cheong HJ; Kim WJ
    Hum Vaccin Immunother; 2019; 15(3):710-716. PubMed ID: 30396317
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Influenza A(H3N2) Antibody Responses to Standard-Dose Versus Enhanced Influenza Vaccine Immunogenicity in Older Adults and Prior Season's Vaccine Status.
    Zhong S; Ng TWY; Skowronski DM; Iuliano AD; Leung NHL; Perera RAPM; Ho F; Fang VJ; Tam YH; Ip DKM; Havers FG; Fry AM; Aziz-Baumgartner E; Barr IG; Peiris M; Thompson MG; Cowling BJ
    J Infect Dis; 2024 May; 229(5):1451-1459. PubMed ID: 37950884
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Use of adjuvanted trivalent influenza vaccine in older-age adults: a systematic review of economic evidence.
    Loperto I; Simonetti A; Nardone A; Triassi M
    Hum Vaccin Immunother; 2019; 15(5):1035-1047. PubMed ID: 30735465
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An Oil-in-Water adjuvant significantly increased influenza A/H7N9 split virus Vaccine-Induced circulating follicular helper T (cT
    Lai L; Rouphael N; Xu Y; Kabbani S; Beck A; Sherman A; Anderson EJ; Bellamy A; Weiss J; Cross K; Mulligan MJ
    Vaccine; 2022 Nov; 40(49):7065-7072. PubMed ID: 36273986
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59 (®) adjuvant: results from a dose-finding clinical trial in older adults.
    Della Cioppa G; Nicolay U; Lindert K; Leroux-Roels G; Clement F; Castellino F; Galli G; Groth N; Del Giudice G
    Hum Vaccin Immunother; 2012 Feb; 8(2):216-27. PubMed ID: 22426371
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparative Immunogenicity of Several Enhanced Influenza Vaccine Options for Older Adults: A Randomized, Controlled Trial.
    Cowling BJ; Perera RAPM; Valkenburg SA; Leung NHL; Iuliano AD; Tam YH; Wong JHF; Fang VJ; Li APY; So HC; Ip DKM; Azziz-Baumgartner E; Fry AM; Levine MZ; Gangappa S; Sambhara S; Barr IG; Skowronski DM; Peiris JSM; Thompson MG
    Clin Infect Dis; 2020 Oct; 71(7):1704-1714. PubMed ID: 31828291
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Compatibility of ASO3-adjuvanted H1N1pdm09 and seasonal trivalent influenza vaccines in adults: results of a randomized, controlled trial.
    Scheifele DW; Ward BJ; Dionne M; Vanderkooi OG; Loeb M; Coleman BL; Li Y;
    Vaccine; 2012 Jul; 30(32):4728-32. PubMed ID: 22652402
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Association between vaccine adjuvant effect and pre-seasonal immunity. Systematic review and meta-analysis of randomised immunogenicity trials comparing squalene-adjuvanted and aqueous inactivated influenza vaccines.
    Beyer WEP; Palache AM; Reperant LA; Boulfich M; Osterhaus ADME
    Vaccine; 2020 Feb; 38(7):1614-1622. PubMed ID: 31879122
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A 21-winter seasons retrospective study of antibody response after influenza vaccination in elderly (60-85 years old) and very elderly (>85 years old) institutionalized subjects.
    Nunzi E; Iorio AM; Camilloni B
    Hum Vaccin Immunother; 2017 Nov; 13(11):2659-2668. PubMed ID: 28922621
    [TBL] [Abstract][Full Text] [Related]  

  • 59. MF59 adjuvanted seasonal and pandemic influenza vaccines.
    Tsai TF
    Yakugaku Zasshi; 2011; 131(12):1733-41. PubMed ID: 22129867
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dissecting the immune response to MF59-adjuvanted and nonadjuvanted seasonal influenza vaccines in children less than three years of age.
    Zedda L; Forleo-Neto E; Vertruyen A; Raes M; Marchant A; Jansen W; Clouting H; Arora A; Beatty ME; Galli G; Del Giudice G; Castellino F
    Pediatr Infect Dis J; 2015 Jan; 34(1):73-8. PubMed ID: 25037034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.